BMY vs CHRS
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. CHRS: A specialized immuno-oncology company driving growth through its FDA-approved PD-1 inhibitor LOQTORZI and a clinical-stage pipeline targeting immune resistance in solid tumors.
Side-by-side fundamentals
| Metric | BMY | CHRS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $61.68 | $1.00 | |
| Market cap | $126.0B | $155M | |
| P/E as of 2026-10-20 | 13.59 | n/a | |
| Net margin FY2025, SEC XBRL | +14.6% | n/a | |
| ROE FY2025, SEC XBRL | +38.2% | +275.4% | CHRS higher |
| ROA FY2025, SEC XBRL | +7.8% | +65.0% | CHRS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.97 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.4% | n/a | |
| Dividend yield as of 2026-09-03 | +4.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | BMY higher |
| Beta as of 2026-09-03 | 0.25 | 1.50 | |
| 1-year return as of 2026-10-20 close | +41.5% | -44.1% | BMY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.